| Balance sheet (USD) | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 | Q2 2024 ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.80B | 8.52B | 7.51B | 6.95B | 6.53B | 7.62B | 7.56B | 6.99B |
| Short-term investments | 492.00M | 417.00M | 222.00M | 331.00M | 312.00M | 351.00M | 230.00M | 232.00M |
| Receivables | 8.21B | 7.93B | 8.14B | 7.97B | 7.33B | 6.92B | 7.05B | 6.85B |
| Inventory | 6.99B | 6.49B | 6.71B | 6.95B | 6.64B | 6.19B | 6.81B | 6.81B |
| Total current assets | 25.51B | 26.00B | 24.84B | 24.47B | 23.15B | 23.66B | 23.80B | 23.12B |
| Property, plant and equipment | 12.38B | 11.82B | 11.50B | 11.39B | 10.93B | 10.66B | 10.62B | 10.23B |
| Goodwill and intangibles | 53.10B | 29.56B | 29.57B | 29.87B | 29.62B | 29.75B | 31.01B | 31.14B |
| Total assets | 110.43B | 86.71B | 84.18B | 84.00B | 81.45B | 81.41B | 74.36B | 73.02B |
| Total current liabilities | 18.38B | 16.50B | 14.58B | 13.44B | 13.00B | 14.16B | 14.90B | 13.76B |
| Long-term debt | 29.64B | 9.90B | 11.60B | 12.93B | 12.74B | 12.63B | 12.82B | 13.14B |
| Total liabilities | 58.37B | 34.58B | 33.23B | 33.43B | 32.64B | 33.75B | 34.56B | 33.70B |
| Retained earnings | 49.96B | 49.78B | 49.10B | 48.47B | 47.72B | 47.26B | 39.06B | 38.35B |
| Shareholders' equity | 52.06B | 52.13B | 50.95B | 50.56B | 48.81B | 47.66B | 39.80B | 39.32B |
| Total debt | 34.05B | 12.93B | 12.94B | 13.44B | 13.24B | 14.13B | 14.98B | 14.75B |
| Net debt | 27.24B | 4.41B | 5.43B | 6.49B | 6.71B | 6.51B | 7.42B | 7.77B |
From Abbott Laboratories's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.